Article

Serenoa repens for benign prostatic hyperplasia

Center for Chronic Disease Outcomes Research (111-0), Minneapolis Veterans Affairs Medical Center, One Veterans Drive, Minneapolis, MN 55417, USA.
Cochrane database of systematic reviews (Online) (Impact Factor: 5.94). 01/2009; DOI: 10.1002/14651858.CD001423.pub2
Source: PubMed

ABSTRACT Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common. The extract of the berry of the American saw palmetto, or dwarf palm plant, Serenoa repens (also known by its botanical name of Sabal serrulatum), is one of several phytotherapeutic agents available for the treatment of BPH.
This systematic review aimed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH.
Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, and The Cochrane Library), by checking bibliographies, and by handsearching the relevant literature.
Trials were eligible if they (1) randomized men with symptomatic BPH to receive preparations of Serenoa repens (alone or in combination) for at least four weeks in comparison with placebo or other interventions, and (2) included clinical outcomes such as urologic symptom scales, symptoms, and urodynamic measurements. Eligibility was assessed by at least two independent observers.
Information on patients, interventions, and outcomes was extracted by at least two independent reviewers using a standard form. The main outcome measure for comparing the effectiveness of Serenoa repens with placebo or other interventions was the change in urologic symptom-scale scores. Secondary outcomes included changes in nocturia and urodynamic measures. The main outcome measure for side effects or adverse events was the number of men reporting side effects.
In this update 9 new trials involving 2053 additional men (a 64.8% increase) have been included. For the main comparison - Serenoa repens versus placebo - 3 trials were added with 419 subjects and 3 endpoints (IPSS, peak urine flow, prostate size). Overall, 5222 subjects from 30 randomized trials lasting from 4 to 60 weeks were assessed. Twenty-six trials were double blinded and treatment allocation concealment was adequate in eighteen studies.Serenoa repens was not superior to placebo in improving IPSS urinary symptom scores, (WMD (weighted mean difference) -0.77 points, 95% CI -2.88 to 1.34, P > 0.05; 2 trials), finasteride (MD (mean difference) 0.40 points, 95% CI -0.57 to 1.37, P > 0.05; 1 trial), or tamsulosin (WMD -0.52 points, 95% CI -1.91 to 0.88, P > 0.05; 2 trials).For nocturia, Serenoa repens was significantly better than placebo (WMD -0.78 nocturnal visits, 95% CI -1.34 to -0.22, P < 0.05; 9 trials), but with the caveat of significant heterogeneity (I(2) = 66%). A sensitivity analysis, utilizing higher quality, larger trials (>/= 40 subjects), demonstrated no significant difference (WMD -0.31 nocturnal visits, 95% CI -0.70 to 0.08, P > 0.05; 5 trials) (I(2) = 11%). Serenoa repens was not superior to finasteride (MD -0.05 nocturnal visits, 95% CI -0.49 to 0.39, P > 0.05; 1 trial), or to tamsulosin (per cent improvement) (RR) (risk ratio) 0.91, 95% CI 0.66 to 1.27, P > 0.05; 1 trial).Comparing peak urine flow, Serenoa repens was not superior to placebo at trial endpoint (WMD 1.02 mL/s, 95% CI -0.14 to 2.19, P > 0.05; 10 trials), or by comparing mean change (WMD 0.31 mL/s, 95% CI -0.56 to 1.17, P > 0.05; 2 trials).Comparing prostate size at endpoint, there was no significant difference between Serenoa repens and placebo (MD -1.05 cc, 95% CI -8.84 to 6.75, P > 0.05; 2 trials), or by comparing mean change (MD -1.22 cc, 95% CI -3.91 to 1.47, P > 0.05; 1 trial).
Serenoa repens was not more effective than placebo for treatment of urinary symptoms consistent with BPH.

0 Followers
 · 
249 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to examine the effects of a green and black tea extract blend [AssuriTEA Men's Health (AMH)] in men with lower urinary tract symptoms (LUTS).
    Therapeutic Advances in Urology 06/2014; 6(3):89-96. DOI:10.1177/1756287214526924
  • [Show abstract] [Hide abstract]
    ABSTRACT: The interaction between lower urinary tract symptoms (LUTS), often caused by benign prostatic hyperplasia (BPH), and sexual dysfunction is today an increasingly well-documented clinical reality. This interaction is based on several factors, all with a clinical incidence: epidemiological since more than 50 % of men 50 years or older can present this association, physiopathological with erectile dysfunction (ED) (BPH is a risk factor independent of ED) and with ejaculation disorders (nearly 46 % of patients presenting LUTS), and a cognitive factor stemming from the strong sociocultural connections related to self-identity between LUTS, ED, and aging. This article provides to the medical sexologist a clinical approach to recognize, evaluate, and integrate LUTS when they are present in a patient consulting for sexual dysfunction. The sexual medicine practicioner is often on the front line to screen for LUTS through management of sexual dysfunction and can also alert the family physician and urologist to the importance of the quality of sexual life for these patients. Nonetheless, it is fundamental that the sexual medicine practicioner be able to facilitate a reflection on the choice of therapy with the family physician and the urologist, mandatory for patients to receive the best possible care.
    Sexologies 09/2014; 23(3):134–139. DOI:10.1016/j.sexol.2014.07.003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Benign prostate hyperplasia (BPH) is a common condition affecting older men, with an incidence that is age-dependent. Histological BPH, which typically develops after the age of 40 years, ranges in prevalence from >50% at 60 years to as high as 90% by 85 years of age. Typical symptoms include increased frequency of urination, nocturia, urgency, hesitancy, and weak urine stream. Conventional medicines used for the treatment of BPH include alpha blockers and 5-alpha reductase inhibitors. This articles review the mode of action, the efficacy, and the safety, including herb-drug interactions of the most common botanicals (Serenoa repens, Pygeum africanum, Urtica dioica, and Cucurbita pepo) and nutraceuticals (isoflavones, lycopene, selenium, and β-Sitosterol) in controlling the lower urinary tract symptoms associated to BPH. Copyright © 2013 John Wiley & Sons, Ltd.
    Phytotherapy Research 07/2014; 28(7). DOI:10.1002/ptr.5084 · 2.40 Impact Factor

Full-text (2 Sources)

Download
198 Downloads
Available from
May 28, 2014